Market Newsdesk

NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.

Effective July 1, 2026, in connection with commencing employment as Head of Product of BetterHelp, David Packles was granted an award of restricted stock units covering 50,000 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”). The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The award was approved by the Compensation Committee of the Board of Directors of Teladoc Health and was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as an employment inducement award pursuant to New York Stock Exchange Rule 303A.08.

About Teladoc Health

Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.

Media:

Lou Serio
202-569-9715
[email protected]

TEL AVIV, Israel, July 03, 2026 (GLOBE NEWSWIRE) — REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”), an automotive technology company that develops and builds software-defined vehicle technology, today announced that it has received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that due to the fact that it  has not regained compliance with Nasdaq Listing Rule 5550(a)(2), the Nasdaq staff has determined to delist the Company’s Class A ordinary shares (the “Ordinary Shares”) from The Nasdaq Capital Market (the “Delisting Determination”) and its Ordinary Shares will be suspended from trading on the Nasdaq Capital Market on July 7, 2026.

As previously reported, the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price for its Ordinary Shares was below $1.00 per share (the “Minimum Bid Price Requirement”) for 30 consecutive business days beginning on May 15, 2025 through June 27, 2025. On July 1, 2025, Nasdaq notified the Company that the closing bid price of its Ordinary Shares had been below $1.00 for 30 consecutive business days, triggering a deficiency under the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial 180-day period, through December 29, 2025, to regain compliance. On December 30, 2025, Nasdaq determined that REE met all other applicable continued listing criteria and was therefore eligible for an additional 180-day extension, through June 29, 2026, to cure the deficiency. Because the Company has not regained compliance with the Minimum Bid Price Requirement during the additional 180-days compliance period, Nasdaq sent the Delisting Determination on June 30, 2026.

The Company may request a hearing before the Nasdaq Hearings Panel by July 7, 2026, but does not intend to do so. The trading of the Company’s Ordinary Shares will be suspended on the Nasdaq Capital Market at the opening of business on July 7, 2026, and Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.

About REE Automotive

REE Automotive (Nasdaq: REE) is an automobile technology company that develops and produces cutting edge software-defined vehicle, or SDV, technology that manages vehicle operations and features through proprietarily-developed software, enabling what we believe to be safer, more modular, and better performing vehicles. Our advanced SDV technology utilizes zonal architecture to enhance redundancy and stability and it contains the capabilities for updates and improvements over-the-air throughout an SDV’s lifespan. This makes Powered by REE® vehicles highly adaptable to customer and market changes and our technology is designed in an effort to be future proofed, autonomous capable. As the first company to FMVSS certify a full by-wire vehicle in the U.S., REE’s proprietary by-wire technology for drive, steer and brake control eliminates the need for mechanical connection. Our approach of “complete not compete” allows original equipment manufacturers, or OEMs, and technology companies to license our technology in order to design and build vehicles reliant upon our SDV technology to their specific requirements and needs. To learn more about REE Automotive’s patented technology and unique value proposition that position the Company to break new ground in e-mobility, visit www.ree.auto.

Media Contact

Keren Shemesh
Chief Marketing Officer for REE Automotive
[email protected]

Investor Contact

Hai Aviv
Chief Finance Officer for REE Automotive
[email protected]

SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) — On January 27, 2026, investors in Commvault Systems, Inc. (NASDAQ: CVLT) suffered a devastating 31% stock price collapse after the company delivered disappointing quarterly results.

Since this time, company executives have unloaded millions of dollars in personal stock holdings, as the company faces a federal securities class action alleging it misled investors about its growth prospects.

Hagens Berman is investigating the claims pled in the pending suit and encourages Commvault investors who suffered substantial losses to submit your losses now.

Class Period: Apr. 29, 2025 – Jan. 26, 2026
Lead Plaintiff Deadline: July 17, 2026
Visit:www.hbsslaw.com/investor-fraud/cvlt
Contact the Firm Now: [email protected]
                                        844-916-0895
View our latest video summary of the allegations: youtu.be/YILiBV90q2w

Over $9.4 Million in Recent Executive Stock Sales

According to publicly filed insider trading reports, Commvault’s top executives — including its CEO, CFO, and Chief Accounting Officer — have collectively sold over $9.4 million in company shares between February and May 2026:

• Sanjay Mirchandani, President & CEO — sold approximately 72,874 shares totaling over $7,015,973 across five separate transactions between February and May 2026.
• Gary Merrill, Chief Financial Officer — sold approximately 20,474 shares totaling over $2,101,458 across four transactions during the same period.
• Danielle Nicole Abrahamsen, Chief Accounting Officer — sold approximately 2,951 shares totaling over $305,668 across four transactions during the same period.

Commvault Systems, Inc. (CVLT) Securities Class Action:

These insider sales come against the backdrop of a securities class action lawsuit filed on behalf of investors who purchased Commvault securities between April 29, 2025, and January 26, 2026.

The lawsuit alleges Commvault’s class period disclosures violated federal securities laws by creating a misleading impression about the company’s growth trajectory. Specifically, the complaint alleges that during the Class Period, Commvault repeatedly touted that its “execution has never been better across the business,” claimed it would “continue to see hyper-growth within [its] SaaS platform,” and promoted its ARR growth and accelerated SaaS target achievement “two quarters earlier than planned.”

The truth allegedly emerged on January 27, 2026, when Commvault reported Q3 2026 financial results revealing a significant miss in net new ARR, a reduction in full-year ARR growth guidance, and a dramatic deceleration in SaaS ARR year-over-year growth — plunging from 71% to just 40%. The company revealed for the first time that the composition of its sales activity materially impacted ARR, with volumes increasingly coming from dramatically lower-priced SaaS deals and heavily discounted long-term contracts.

Several analysts reportedly characterized the results as a “mess” and questioned Commvault’s ability to execute, promptly downgrading the stock.

HBSS Investigation

“We’re investigating whether Commvault misled investors regarding its ARR growth by masking the impact of lower-priced SaaS deals and heavy discounting, as the complaint alleges,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Commvault and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to frequently asked questions about the Commvault case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Commvault should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) — Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit follows the company’s disastrous Q2 2026 earnings report, apparently at odds with prior narrative, which triggered a massive selloff in the stock and analysts’ questions.

These developments have prompted national shareholder rights firm Hagens Berman to open an investigation into claims that Embecta violated the federal securities laws.

The firm encourages Embecta investors who suffered substantial losses to submit your losses now.

Embecta Corp. (EMBC) Securities Class Action:

Embecta is a global medical device company whose core business product is pen needles – sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. In the past, pen needle revenues have comprised over 70% of the company’s total revenues.

The litigation’s primary focus is on the propriety of Embecta’s Class Period repeated assurances that “insulin pens have been stable […] showing the underlying resilience and the durability of that portfolio[]” and “our pen needle business is incredibly resolute.” This narrative formed the basis for the company’s February 5, 2026 guidance reiterating 2026 adjusted EPS of $2.80 – $3.00. The company also touted maintenance of its dividend within its capital allocation plans as a return of capital to shareholders.

The complaint alleges the company’s assurances and guidance were misleading when given because Embecta knew or recklessly disregarded that weaknesses in the pen needle market was likely to significantly disrupt the company’s annual guidance and Q2 results.

On May 5, 2026, investors’ expectations vanished. That day, Embecta reported Q2 2026 adjusted EPS of $0.27, a staggering sequential and year-over-year decline of about 61%. In contrast to the company’s assurances of stability, resilience, and durability, Embecta’s pen needles revenues also suffered massive sequential and year-over-year declines. Of additional concern, Embecta slashed its 2026 adjusted EPS guidance to $1.55 – $1.75, or down roughly 43% at the mid-point, and reduced its dividend by 93% to just $0.01.

In response, the market sent the price of Embecta shares tumbling, with one prominent analyst who downgraded the company highlighting Embecta management’s “need to rebuild investor credibility on commercial execution and the profitability outlook.”

“Our investigation is focused the extent to which and when Embecta and its management knew about pen needle and U.S. business revenue headwinds, and whether they were sufficiently transparent about those risks,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Embecta and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Embecta case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Embecta should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) — Hagens Berman, a recognized leader in securities litigation, is actively investigating claims pled in an investor class action alleging that PicS N.V. (NASDAQ: PICS) January 30, 2026, Initial Public Offering (IPO) documents contained misrepresentations and omissions.

CLICK HERE TO SUBMIT YOUR PICS IPO LOSSES TO HBSS

Lead Plaintiff Deadline: Aug. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/pics
Contact the Firm Now: [email protected]
                                       844-916-0895

PicS N.V. (PICS) Securities Class Action: IPO Disclosure vs. Internal Reality

The PICS securities class action focuses on the propriety of PicS’ disclosures concerning the sufficiency of its credit evaluation procedures, allowance for expected credit losses (“ECL”), and classification of financial assets into Stage 1 (no significant increase in credit risk since recognition), Stage 2 (significant increase in credit risk subsequent to recognition) and Stage 3 (credit impaired).

The complaint alleges that, unknown to investors, PicS had evaluated its credit evaluation procedures before the IPO. During December 2025, PicS determined they were deficient and required enhancement.

In addition, the complaint alleges that PicS’ enhancement procedures resulted in the company reclassifying approximately R$590 million of exposures from Stage 2 to Stage 3 and resulted in an incremental ECL charge of R$88 million in the three months ended December 31, 2025.

Moreover, the complaint alleges PicS experienced a heightened and undisclosed Stage 3 formation rate showing new contracts entering default spiking from 3.8% in Q3 2025 to over 7% in Q4 2025. The metric substantially deviated from the results and trends disclosed in the IPO offering documents.

On March 19, 2026, PicS filed its financial results for its Q4 and FY 2025, which both ended before the IPO. The company’s Stage 2 to Stage 3 reclassifications as well as its spike in defaulting Stage 3 loans were among the matters revealed in the filing.

Then, on June 2, 2026, PicS announced its Q1 2026 results revealing significant additional deterioration in credit quality and a massive 13% spike in Stage 3 loans.

“We’re focused on whether PicS’ IPO documents were negligently prepared for failing to disclose adverse facts about its credit evaluation processes,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in PicS and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the PicS case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding PicS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) — Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential.

The suit follows a devastating 49% stock collapse on May 5, 2026 in response to the company’s disastrous Q1 2026 earnings report, including a $31.2 million impairment charge.

The firm urges GeneDx investors who suffered significant losses to contact the firm now.

Class Period: Apr. 16, 2025 – May 4, 2026
Lead Plaintiff Deadline: Aug. 3, 2026
Visit:www.hbsslaw.com/investor-fraud/wgs
Contact the Firm Now:[email protected]
                                       844-916-0895

The GeneDx Securities Class Action: The Fabrics Genomics Discrepancy

The complaint alleges that GeneDx falsely touted the acquisition of Fabric Genomics as a cornerstone of its efficiency and future profitability.

But on May 4, 2026, GeneDx reported dismal Q1 2026 financial results which included a massive tenfold increase in net loss compared to the prior year period. The Fabric Genomics business (which reported a $2.5 million revenue miss) was the largest contributor to the loss, as GeneDx recorded impairment charges related to the unit totaling $31.2 million, or about 94% of the cash paid for it just one year ago.

In addition, GeneDx’s ARR fell about $200 short, a surprise blamed on a huge, adverse change in product mix toward genome whose ARR was only half that of exome. The company also said that exome and genome revenue growth would be “at least 20%,” substantially lower than it said as recently as February. As a result of GeneDx’s changed growth narrative, the company slashed 2026 revenue guidance by 12%.
Leadership Maneuver

In the wake of the stock price cratering, GeneDx recently appointed a new President, Mark Gardner. Hagens Berman is investigating whether this leadership change is causally related to alleged failures that preceded the May collapse.

“The complaint alleges that investors were sold a vision of technological synergy, only to be hit with a massive impairment charge,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation. “We’re investigating whether GeneDx’s leadership knew of a disconnect between their public projections and the internal reality of their acquisitions.”

If you invested in GeneDx and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the GeneDx case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding GeneDx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895